Navigation Links
Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be
Date:2/9/2011

tials

2%(2%)4%   Research Specialties

3%(2%)5%   Research Biotech

(2%)-(2%)   Research Chemicals2%(1%)3%   SAFC

2%(2%)4%   Total Customer Sales2%(1%)3%Twelve MonthsEnded December 31, 2010CurrencyAdjustedReportedImpact(Organic)   Research Essentials

2%-2%   Research Specialties

6%-6%   Research Biotech

3%1%2%   Research Chemicals4%-4%   SAFC

9%-9%   Total Customer Sales6%1%5%Business Unit Sales(in millions)First
Quarter 2010Second
Quarter 2010Third
Quarter 2010Fourth
Quarter 2010Total
2010   Research Essentials

$
2$
7$
5$$
434   Research Specialties

217207207214845   Research Biotech

91838487345   Research Chemicals4203973964111,624   SAFC

152157167171647   Total Customer Sales$
572$
554$
563$
582$
2,271First
Quarter 2009Second
Quarter 2009Third
Quarter 2009Fourth
Quarter 2009Total
2009   Research Essentials

$
7$$
4$
8$
425   Research Specialties

197193198208796   Research Biotech

82808389334   Research Chemicals3863793854051,555   SAFC

133143149168593   Total Customer Sales$
519$
522$
534$
573$
2,148SIGMA-ALDRICH CORPORATIONSupplemental Financial Information - (Unaudited)Reconciliation of Reported net income to Adjusted net incomeNet IncomeDiluted Earnings (in millions)Per ShareThree Months EndedThree Months EndedDecember 31,December 31,2010200920102009Reported net income$
94$
93$
.76$
.75Restructuring costs

860.070.05Adjusted net income

$
2$
99$
.83$
.80Included above:Currency impact

$
(2)$
-$
(0.02)$
-Net IncomeDiluted Earnings (in millions)Per ShareTwelve Months EndedTwelve Months EndedDecember 31,December 31,2010200920102009Reported net income$
384$
347$
3.12$
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Sigma-Aldrich to Present at the JP Morgan 29th Annual Healthcare Conference on Monday, January 10, 2011.
2. Sigma-Aldrich Acquires Cerilliant Corporation to Strengthen its Analytical Chemistry Portfolio
3. Sigma-Aldrich Corporation Announces Death of Chairman and CEO; Election of New CEO and Chairman; Conference Call Scheduled for 10:00a.m. (Central Time) on November 15, 2010
4. Sigma-Aldrich Announces Pricing of Senior Notes
5. Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 -
6. Sigma-Aldrich to Present at the UBS Global Life Sciences Healthcare Conference on Tuesday, September 21, 2010
7. Sigma-Aldrich Announces Appointment of Magnus Borg as Vice President and Chief Information Officer (CIO)
8. Sigma-Aldrich Corporation to Present at the Bairds 2010 Growth Stock Conference on Thursday, May 20, 2010
9. Sigma-Aldrich (Nasdaq: SIAL) Announces Executive Management Changes: Retirement of David Julien and Promotion of Joseph Porwoll
10. Sigma-Aldrich to Present at the Bank of America Merrill Lynch 2010 Health Care Conference on Wednesday, May 12, 2010
11. Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pursuit ... selling optimization technology and services for Life Sciences ... “Grading Pharma’s Use of New Commercial Sales Models” ... & Analytics. , The article examines some innovative ... that are being tested in the pharmaceutical market. ...
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/21/2014)... On Wednesday of last week RENU 28, ... Signaling molecules, became available for purchase in Australia and New ... that RENU 28 works is, if you think about the ... rate of cellular renewal within your body. If you think ... rate of cellular renewal. What RENU 28 does is it ...
(Date:8/20/2014)... An analysis of patented university inventions licensed to ... path to commercialization. To open these roadblocks, the ... results during the discovery stage could lead to ... are frequently derived from discoveries made in university ... well known during clinical trials, which have a ...
Breaking Biology Technology:Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... DRRX ) announced today that a New ... submitted to the U.S. Food,and Drug Administration (FDA). ... formulation of oxycodone intended to treat moderate to ... designed to resist,common methods of prescription drug misuse ...
... to advance Merrimack,s robust pipeline of biologics ... targeting autoimmune disease and cancer, CAMBRIDGE, Mass., ... the discovery and development of,novel treatments for autoimmune disease and ... Series F private equity financing., Existing and new investors ...
... Bioheart, Inc.,(Nasdaq: BHRT ) today announced that ... common stock to the Nasdaq Capital Market. The Company,s,common ... to The,Nasdaq Capital Market at the opening of business ... a tier of the Nasdaq Stock Market for,companies with ...
Cached Biology Technology:New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 2New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 4New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 5Merrimack Pharmaceuticals Raises $60 Million in Private Financing 2Bioheart, Inc. to Transfer to Nasdaq Capital Market 2
(Date:8/21/2014)... -- Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication company ... that its shares of common stock and the warrants ... proposed underwritten public offering of common stock and warrants ... Market, subject to closing of its proposed underwritten public ... trade under the symbol "NXTD" and "NXTDW," respectively. ...
(Date:8/21/2014)... aimed at improving the food intake, health and quality ... is among three projects at the University of Waterloo ... Canadian Institutes of Health Research (CIHR). , Professor ... at Waterloo, and a Schlegel research chair in nutrition ... investigate why many Canadians living in long-term care homes ...
(Date:8/21/2014)... Wednesday, Oct. 18-22, 2014 , WHERE: , ... San Diego, CA 92101 , WHAT: , ... of the latest research in human genetics. Examples ... high-scoring abstracts on rare genetic variants in health ... treatment for sun sensitivity (Saturday, Oct. 18, 5:30-7:30 ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2
... (UW) have reported for the first time that mammals can ... retinas. Located in the back of the eye, the retina,s ... to the brain. The findings on retina self-repair in ... of the Proceedings of the National Academy of Sciences ...
... Institute of Technology has invited a longtime University of ... and presenting seminars on its campus. Fazle Hussain, ... Engineering, was the sole recipient of the Gordon and ... for Caltech,s division of engineering and applied sciences. The ...
... University have answered a fundamental question of how important ... function, a finding that could provide a new target ... diseases. In a study published this month in ... show for the first time that the specific movements ...
Cached Biology News:Mammals can be stimulated to regrow damaged inner retina nerve cells 2Mammals can be stimulated to regrow damaged inner retina nerve cells 3Celebrated UH researcher invited to Caltech as distinguished scholar 2Scientists present 'moving' theory behind bacterial decision-making 2
Human Cystatin F MAb (Clone 292103)...
... Ac-DEVD-CHO is an inhibitor ... The concentration of inhibitor ... activity must be determined ... Ten micromolar inhibitor is ...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Mouse NOV/CCN3 Affinity Purified Polyclonal Ab...
Biology Products: